0001722964false00017229642025-01-132025-01-13

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

​

FORM 8-K

​

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

​

Date of report (Date of earliest event reported): January 13, 2025

​

Y-MABS THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware

    

001-38650

    

47-4619612

(State or other jurisdiction of
incorporation or organization)

 

(Commission
File Number)

 

(I.R.S. Employer
Identification No.)

​

230 Park Avenue

Suite 3350

New York, New York 10169

(Address of principal executive offices) (Zip Code)

​

(646) 885-8505

(Registrant’s telephone number, include area code)

​

N/A

(Former name or former address, if changed since last report)

​

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

​

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Securities registered pursuant to Section 12(b) of the Act:

​

Title of each class

    

Trading Symbol(s)

   

Name of each exchange on which registered

Common Stock, $0.0001 par value

 

YMAB

 

Nasdaq Global Select Market

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

​

Emerging growth company  ☐

​

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

​

​

​

Item 7.01 Regulation FD Disclosure.

On January 13, 2025, Y-mAbs Therapeutics, Inc. (the “Company”) made available in the investor relations portion of its website, https://ir.ymabs.com, a corporate overview presentation that the Company plans to use in investor meetings and in its podium presentation at the J.P. Morgan Healthcare Conference. The presentation includes corporate updates, including updates with respect to the Company’s business, clinical trials and development pipeline.

The information furnished pursuant to Item 7.01 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

​

​

SIGNATURES

Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​

 

Y-MABS THERAPEUTICS, INC.

 

 

 

Date: January 13, 2025

By:

/s/ Michael Rossi

 

 

Michael Rossi

 

 

President and Chief Executive Officer

​

​

​

v3.24.4
Document and Entity Information
Jan. 13, 2025
Document and Entity Information [Abstract]  
Document Type 8-K
Document Period End Date Jan. 13, 2025
Entity Registrant Name Y-MABS THERAPEUTICS, INC.
Entity Incorporation, State or Country Code DE
Entity File Number 001-38650
Entity Tax Identification Number 47-4619612
Entity Address, Address Line One 230 Park Avenue
Entity Address, Adress Line Two Suite 3350
Entity Address State Or Province NY
Entity Address, City or Town New York
Entity Address, Postal Zip Code 10169
City Area Code 646
Local Phone Number 885-8505
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.0001 par value
Trading Symbol YMAB
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001722964
Amendment Flag false
Grafico Azioni Y mAbs Therapeutics (NASDAQ:YMAB)
Storico
Da Dic 2024 a Gen 2025 Clicca qui per i Grafici di Y mAbs Therapeutics
Grafico Azioni Y mAbs Therapeutics (NASDAQ:YMAB)
Storico
Da Gen 2024 a Gen 2025 Clicca qui per i Grafici di Y mAbs Therapeutics